Salarius Pharmaceuticals, Inc.
SLRX
$0.86
-$0.01-1.71%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 833.30K | 849.20K | 1.64M | 1.31M | 869.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 895.10K | 965.60K | 1.72M | 1.49M | 1.01M |
| Operating Income | -895.10K | -965.60K | -1.72M | -1.49M | -1.01M |
| Income Before Tax | -873.50K | -957.80K | -1.71M | -1.46M | -972.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -873.50K | -957.80K | -1.71M | -1.46M | -972.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -873.50K | -957.80K | -1.71M | -1.46M | -972.10K |
| EBIT | -895.10K | -965.60K | -1.72M | -1.49M | -1.01M |
| EBITDA | -894.00K | -964.50K | -1.72M | -1.49M | -1.01M |
| EPS Basic | -1.81 | -11.38 | -11.38 | -11.38 | -11.38 |
| Normalized Basic EPS | -1.13 | -- | -- | -- | -7.11 |
| EPS Diluted | -1.81 | -11.38 | -11.38 | -11.38 | -11.38 |
| Normalized Diluted EPS | -1.13 | -- | -- | -- | -7.11 |
| Average Basic Shares Outstanding | 481.60K | -- | -- | -- | 85.50K |
| Average Diluted Shares Outstanding | 481.60K | 85.50K | 85.50K | 85.50K | 85.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |